News Release

 

Back
 

AmerisourceBergen Reports Record March Quarter as Early Synergy Capture and Interest Savings Drive Results

04/25/02

March Quarter EPS Up 53 Percent To $0.87 Before Special Charges

VALLEY FORGE, Pa., Apr 25, 2002 (BUSINESS WIRE) --AmerisourceBergen Corporation (NYSE:ABC) today reported record results for its fiscal second quarter and six months ended March 31, 2002.

AmeriSource Health Corporation and Bergen Brunswig Corporation merged on August 29, 2001 to form AmerisourceBergen Corporation. Under purchase accounting rules, AmerisourceBergen's fiscal 2002 second quarter and six-month results are compared with the fiscal 2001 second quarter and six-month results of AmeriSource only.

Pro forma data included in this discussion reflects comparisons to the combined companies' operating results in the previous year's second quarter and first six months, adjusted to eliminate amortization of goodwill. Both former companies had the same fiscal year ending September 30.

Diluted earnings per share before special charges for the quarter were $0.87, a 53 percent increase over the previous year's second quarter. Income before the special charges for the second quarter increased to $94.7 million from $31.5 million in the same period last year.

The special charges, consisting of merger integration costs, were $2.9 million, net of tax, in the quarter. Net income and diluted earnings per share for the quarter were $91.9 million and $0.84, respectively.

AmerisourceBergen's operating revenue, which excludes bulk deliveries to customer warehouses, was $9.9 billion in the second quarter compared to $3.5 billion for the same period last year. Second quarter operating revenue increased 17 percent over fiscal 2001 second quarter pro forma operating revenue of $8.5 billion.

For the first six months of fiscal 2002, diluted earnings per share before special charges were $1.54, a 44 percent increase over the prior year. Operating revenue for the six-month period was $19.6 billion compared to $6.8 billion in the prior year, and represents an 18 percent increase over pro forma operating revenue of $16.6 billion in the first half of fiscal 2001.

Net income and diluted earnings per share for the six-month period were $159.8 million and $1.48, respectively.

For the second quarter of fiscal 2002, interest expense, including pretax distributions on preferred securities of subsidiary trust, was $38.8 million, reflecting effective asset management and favorable interest rates.

The following discussion of results, including segment data, does not include the impact of the special charges in the second quarter and first six months of fiscal 2002.

R. David Yost, AmerisourceBergen President and Chief Executive Officer, said, "This was an outstanding performance by AmerisourceBergen, reflecting our ability to rapidly leverage the cost saving and scale synergies of our new company. We have succeeded in capturing merger synergies earlier than we expected. Improved capital management and a historically low interest rate environment also positively impacted the Company's performance. These factors drove operating margin expansion, record earnings per share, significant cash generation, and a very strong return on committed capital (ROCC).

"I am very pleased with the progress we are making in bringing these two companies together. Our synergy opportunities and our discipline in both capital usage and expense control will continue to drive our results."

    Segment Discussion
AmerisourceBergen operates in two segments: Pharmaceutical Distribution (which includes AmerisourceBergen Drug Company and AmerisourceBergen Specialty Group) and PharMerica, AmerisourceBergen's institutional pharmacy and workers' compensation fulfillment businesses.

Intersegment sales of $192.1 million in the second quarter of fiscal 2002 from AmerisourceBergen Drug Company to PharMerica, which are included in the pharmaceutical distribution segment operating revenue, are eliminated for consolidated reporting purposes.

    Pharmaceutical Distribution Segment
Operating revenue in the second quarter of fiscal 2002 increased to $9.8 billion compared with $3.5 billion in the previous year's second quarter. Operating revenue increased 17 percent over fiscal 2001 second quarter pro forma revenues of $8.3 billion.

Pharmaceutical distribution customer mix in the second quarter of fiscal 2002 was 52 percent institutional and 48 percent retail. AmerisourceBergen is the market leader in pharmaceutical distribution to hospital systems and acute care facilities, alternate care and mail order facilities, independent community pharmacies, and regional chain store pharmacies.

Operating income was $176.0 million in the second quarter of fiscal year 2002, up from $64.4 million for the same quarter last year, and improved 22 percent compared to pro forma operating income of $144.7 million in the same period last year.

For the fiscal 2002 second quarter, operating income, as a percentage of operating revenue, was 1.80 percent, a six basis point improvement from 1.74 percent in the prior year's second quarter on a pro forma basis, as lower gross margins were more than offset by lower total operating expenses as a percentage of operating revenue.

AmerisourceBergen Specialty Group, with annualized revenue well over $2 billion, had another very strong quarter, building significant positions in oncology, blood plasma and vaccine distribution as well as growing its manufacturing services businesses.

"We are pleased with both the pace and progress of our integration work. Our detailed planning and disciplined execution has allowed us to put the right people, organization and resources in place to quickly capture integration cost savings ahead of our internal schedule," said Kurt J. Hilzinger, AmerisourceBergen Executive Vice President and Chief Operating Officer. "During the quarter, we completed on schedule the information technology integration work that will allow us to consolidate five additional distribution centers by the end of September. The first of these, in Phoenix, Arizona, is on track to be completed this week.

"At the end of the quarter, we launched our new generic pharmaceutical program, ProGenerics(TM), which provides significant value for both our customers and participating manufacturers, and will further contribute to our profitability in the second half of the year."

    PharMerica
PharMerica's operating revenue for the second quarter of fiscal 2002 was $359.8 million, representing a 6 percent increase over pro forma operating revenue of $339.9 million in the same period last year.

Operating income for the second quarter was $19.5 million, a 21 percent increase over the prior year's pro forma second quarter operating income of $16.1 million.

Operating income as a percentage of operating revenue increased 69 basis points in the quarter to 5.43 percent from 4.74 percent on a pro forma basis in the prior year.

"Cost savings from expense control, driven by the favorable impact of a single information technology platform and continued accounts receivables discipline, improved PharMerica's performance in the quarter," said Hilzinger.

    Looking Ahead
"We expect continued strong performance for AmerisourceBergen with revenue growth for fiscal year 2002 in the range of 15 percent to 17 percent and ROCC in excess of 20 percent," said Yost. "We are increasing our diluted earnings per share estimate for fiscal year 2002, excluding the impact of merger-related special charges, from $3.00 to $3.15. The increase in earnings expectations for the year reflects the strong performance of our businesses in the second quarter, continued low interest rates, and our ongoing focus on cost improvement. We remain confident in our ability to achieve annual cost saving synergies of $150 million by the end of fiscal year 2004."

    Conference Call
The Company will host a conference call to discuss the results at 11:00 am Eastern Daylight Time on April 25, 2002. Participating in the conference call will be: R. David Yost, President & Chief Executive Officer; Kurt J. Hilzinger, Executive Vice President & Chief Operating Officer; and Michael D. DiCandilo, Senior Vice President & Chief Financial Officer.

    To access the live conference call via telephone:
Dial in: 888/428-4473 from inside the U.S. no access code required
         or 651/291-0561 from outside the U.S. no access code
         required.
    To access the live webcast:
Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net.

A replay of the telephone call and webcast will be available from 2:30 pm April 25, 2002 until 11:59 pm May 2, 2002.

    To access the replay via telephone:
Dial in: 800/475-6701 from within the U.S., access code: 634155
         320/365-3844 from outside the U.S., access code: 634155
    To access the archived webcast:
Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net.

    About AmerisourceBergen
AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems/acute care market, alternate care and mail order facilities, independent community pharmacies, and regional chain pharmacies.

The Company is also a leader in the institutional pharmacy marketplace. With more than $39 billion in annualized operating revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

    Forward-Looking Statements
This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.

Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger between Amerisource Health Corporation and Bergen Brunswig Corporation.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally.

More detailed information about these factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2001, Form 10-Q for the first quarter of fiscal 2002, and AmeriSource's and Bergen's joint proxy statement-prospectus dated August 1, 2001.

AmerisourceBergen, AmeriSource and Bergen Brunswig are under no obligation to (and expressly disclaim any such obligation to) update or alter their forward-looking statements whether as a result of new information, future events or otherwise.

                     AMERISOURCEBERGEN CORPORATION
                           FINANCIAL SUMMARY
                 (In thousands, except per share data)
                              (unaudited)
                Three                    Three
              Months Ended    % of    Months Ended    % of
               March 31,   Operating    March 31,   Operating     %
                 2002       Revenue       2001       Revenue    Change
              ----------    ------     ----------     ------     ----
Revenue:
 Operating
  revenue     $9,918,609    100.00%    $3,480,685     100.00%    185%
 Bulk
  deliveries
  to
  customer
  warehouses   1,025,658                      313                   -
              ----------               ----------
Total revenue 10,944,267                3,480,998                 214%
Cost of goods
 sold         10,429,774                3,329,829                 213%
              ----------               ----------
Gross profit     514,493      5.19%       151,169       4.34%     240%
Operating
 expenses:
  Distribution,
   selling and
  administrative 304,576      3.07%        82,462       2.37%     269%
  Depreciation
   and
   amortization   14,402      0.15%         4,281       0.12%     236%
  Merger costs     4,741      0.05%             -       0.00%       -
              ----------               ----------
Operating
 income          190,774      1.92%        64,426       1.85%     196%
Equity in
 (income)
 losses of
 affiliates
 and other          (354)     0.00%         1,801       0.05%    -120%
Interest
 expense          32,734      0.33%        11,793       0.34%     178%
              ----------               ----------
Income before
 taxes and
 distributions
 on preferred
 securities of
 subsidiary
 trust           158,394      1.60%        50,832       1.46%     212%
Income taxes      62,891      0.63%        19,316       0.55%     226%
              ----------               ----------
Income before
 distributions
 on preferred
 securities
 of subsidiary
 trust            95,503      0.96%        31,516       0.91%     203%
Distributions on
 preferred
 securities of
 subsidiary
 trust, net of
 income tax
 benefit of
 $2,389            3,629      0.04%             -       0.00%       -
              ----------               ----------
Net income    $   91,874      0.93%    $   31,516       0.91%     192%
              ==========               ==========
Earnings
 per share:
  Basic       $     0.88               $     0.60
  Diluted     $     0.84               $     0.57
Weighted
 average
 common
 shares
 outstanding:
  Basic          104,404                   52,701
  Diluted        111,704                   59,349
----------------------------------------------------------------------
Pro forma results excluding merger costs in the three months ended
March 31, 2002:
Operating
 income       $  195,515               $   64,426
Net income    $   94,734               $   31,516
Earnings per
 share:
  Basic       $     0.91               $     0.60
  Diluted     $     0.87               $     0.57
                     AMERISOURCEBERGEN CORPORATION
                           FINANCIAL SUMMARY
                 (In thousands, except per share data)
                              (unaudited)
                       Six                    Six
                   Months Ended   % of    Months Ended  % of
                    March 31,  Operating   March 31,   Operating   %
                      2002      Revenue      2001       Revenue Change
                  ------------ --------- ------------ --------- ------
Revenue:
  Operating
   revenue          $19,604,885  100.00%  $6,787,436  100.00%     189%
  Bulk
   deliveries
   to customer
   warehouses         2,408,162                  757               --
                    -----------           ----------
Total revenue        22,013,047            6,788,193              224%
Cost of
 goods sold          21,027,121            6,499,591              224%
                    -----------           ----------
Gross profit            985,926    5.03%     288,602    4.25%     242%
Operating
 expenses:
  Distribution,
   selling
   and
   administrative       602,168    3.07%     162,107    2.39%     271%
  Depreciation
   and
   amortization          29,449    0.15%       8,175    0.12%     260%
  Merger costs           12,238    0.06%          --    0.00%      --
                    -----------           ----------
Operating
 income                 342,071    1.74%     118,320    1.74%     189%
Equity in
 losses
 of affiliates
 and
 other                    1,377    0.01%       2,575     0.04%    -47%
Interest
 expense                 63,709    0.32%      22,669     0.33%    181%
                    -----------           ----------
Income
 before
 taxes
 and
 distributions
 on preferred
 securities of
 subsidiary
 trust                  276,985    1.41%      93,076    1.37%     198%
Income taxes            109,969    0.56%      35,369    0.52%     211%
                    -----------           ----------
Income before
 distributions
 on
 preferred
 securities
 of subsidiary
 trust                  167,016    0.85%      57,707    0.85%     189%
Distributions
 on
 preferred
 securities
 of
 subsidiary
 trust,
 net of
 income tax
 benefit
 of $4,777                7,259    0.04%          --    0.00%      --
                    -----------           ----------
Net income             $159,757    0.81%     $57,707    0.85%     177%
                    ===========           ==========
Earnings per
 share:
  Basic                   $1.54                $1.10
  Diluted                 $1.48                $1.07
Weighted average
 common shares
 outstanding:
  Basic                 104,070               52,528
  Diluted               111,443               56,939
----------------------------------------------------------------------
Pro forma results excluding merger costs in the six months ended March
31, 2002:
Operating income       $354,309             $118,320
Net income             $167,137              $57,707
Earnings per share:
  Basic                   $1.61                $1.10
  Diluted                 $1.54                $1.07
                     AMERISOURCEBERGEN CORPORATION
                 CONDENSED CONSOLIDATED BALANCE SHEETS
                        (dollars in thousands)
                   ASSETS      (Unaudited)
                                 March 31,  September 30,         $
                                   2002         2001           Change
                                 ---------  -------------      ------
Current assets:
 Cash and cash equivalents    $   463,815   $   297,626   $   166,189
 Accounts receivable, net       2,061,331     2,142,663       (81,332)
 Merchandise inventories        5,295,924     5,056,257       239,667
 Prepaid expenses and other        17,831        15,956         1,875
                              -----------   -----------   -----------
    Total current assets        7,838,901     7,512,502       326,399
Long-term assets                2,761,318     2,778,743       (17,425)
                              -----------   -----------   -----------
    Total assets              $10,600,219   $10,291,245   $   308,974
                              ===========   ===========   ===========
      LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
 Accounts payable             $ 5,076,767   $ 4,991,884   $    84,883
 Current portion of
  long-term debt                   30,000         2,468        27,532
 Other current
  liabilities                     616,625       538,101        78,524
                              -----------   -----------   -----------
    Total current
     liabilities                5,723,392     5,532,453       190,939
Long-term debt, less
 current portion                1,508,889     1,597,295       (88,406)
Other liabilities                  43,260        48,317        (5,057)
Company-obligated
 mandatorily redeemable
 preferred securities
 of subsidiary trust              274,952       274,616           336
Stockholders' equity            3,049,726     2,838,564       211,162
                              -----------   -----------   -----------
    Total liabilities
     and stockholders'
     equity                   $10,600,219   $10,291,245   $   308,974
                              ===========   ===========   ===========
                     AMERISOURCEBERGEN CORPORATION
                      SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)
                              Three Months Ended March 31,
               -------------------------------------------------------
Operating         Actual     Actual     Pro forma   Actual   Pro forma
Revenue            2002       2001       2001 (1)  % Change  % Change
-------------- -------------------------------------------------------
Pharmaceutical
 Distribution  $9,750,903  $3,480,685  $8,335,337    180%        17%
PharMerica        359,761          -      339,924     -           6%
Intersegment
 Eliminations    (192,055)         -     (207,285)    -          -7%
               ----------- ----------  -----------  ------------------
  Operating
   revenue     $9,918,609  $3,480,685  $8,467,976    185%        17%
               =========== ==========  ===========  ==================
                               Three Months Ended March 31,
               -------------------------------------------------------
Operating         Actual     Actual     Pro forma   Actual   Pro forma
Income (2)         2002       2001       2001 (1)  % Change  % Change
-------------- -------------------------------------------------------
Pharmaceutical
 Distribution    $175,968     $64,426    $144,714    173%        22%
PharMerica         19,547          -       16,114     -          21%
               ----------- ----------  -----------  ------------------
  Operating
   income        $195,515     $64,426    $160,828    203%        22%
               =========== ==========  ==========   ==================
Percentages of
operating revenue (2):
Pharmaceutical
 Distribution
  Gross profit      4.04%       4.34%       4.30%
  Operating
   expenses         2.23%       2.49%       2.56%
  Operating income  1.80%       1.85%       1.74%
PharMerica
 Gross profit      33.52%         -        35.81%
 Operating
  expenses         28.09%         -        31.07%
 Operating income   5.43%         -         4.74%
AmerisourceBergen
 Corporation
  Gross profit      5.19%       4.34%       5.67%
  Operating
   expenses         3.22%       2.49%       3.77%
  Operating income  1.97%       1.85%       1.90%
(1) Represents the combination of AmeriSource Health Corporation's
    and Bergen Brunswig Corporation's previously reported financial
    information.  (See discussion under Pro Forma Information
    Appendix - A(1)).
(2) Excludes merger costs.
                     AMERISOURCEBERGEN CORPORATION
                      SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)
                                Six Months Ended March 31,
                ------------------------------------------------------
                   Actual       Actual    Pro forma    Actual    Pro
Operating Revenue   2002         2001       2001 (1)     %      forma
                                                       Change    %
                                                               Change
--------------  ------------------------------------------------------
Pharmaceutical
 Distribution   $19,272,979  $ 6,787,436  $16,265,303   184%    18%
PharMerica          715,176            -      675,090      -     6%
Intersegment
 Eliminations      (383,270)           -     (388,882)     -    -1%
                -----------  -----------  -----------  -----------
  Operating
   revenue      $19,604,885  $ 6,787,436  $16,551,511   189%    18%
                ===========  ===========  ===========  ===========
                                  Six Months Ended March 31,
                ------------------------------------------------------
                   Actual       Actual    Pro forma    Actual    Pro
Operating           2002         2001      2001 (1)      %      forma
 Income (2)                                            Change      %
                                                                Change
-------------- -------------------------------------------------------
Pharmaceutical
 Distribution   $   315,452  $   118,320  $   260,804   167%    21%
PharMerica           38,857            -       33,221     -     17%
                -----------  -----------  -----------  -----------
  Operating
   income       $   354,309  $   118,320  $   294,025   199%    21%
                ===========  ===========  ===========  ===========
Percentages
 of operating
 revenue (2):
Pharmaceutical
 Distribution
  Gross profit         3.87%        4.25%        4.18%
  Operating
   expenses            2.23%        2.51%        2.58%
  Operating income     1.64%        1.74%        1.60%
PharMerica
  Gross profit        33.57%           -        35.83%
  Operating expenses  28.14%           -        30.91%
  Operating income     5.43%           -         4.92%
AmerisourceBergen
 Corporation
  Gross profit         5.03%        4.25%        5.57%
  Operating expenses   3.22%        2.51%        3.80%
  Operating income     1.81%        1.74%        1.78%
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
(2) Excludes merger costs.
                     AMERISOURCEBERGEN CORPORATION
                          EARNINGS PER SHARE
                 (In thousands, except per share data)
                              (unaudited)
	   Basic earnings per share is computed on the basis of the weighted
average number of shares of common stock outstanding during the
periods presented. Diluted earnings per share is computed on the basis
of the weighted average number of shares of common stock outstanding
during the period plus the dilutive effect of stock options.
Additionally, the calculations consider the convertible subordinated
notes as if converted and, therefore, the effect of interest expense
related to those notes is added back to net income in determining
income available to common stockholders.
                              Three months ended    Six months ended
                                  March 31,             March 31,
                               2002       2001       2002       2001
                             --------   --------   --------   --------
Net income                   $ 91,874   $ 31,516   $159,757   $ 57,707
Interest expense
 - convertible
 subordinated
 notes, net of
 income taxes                   2,481      2,528      4,961      3,086
                             --------   --------   --------   --------
Income available
 to common
 stockholders                $ 94,355   $ 34,044   $164,718   $ 60,793
                             ========   ========   ========   ========
Weighted average
 common shares
 outstanding                  104,404     52,701    104,070     52,528
Effect of
 dilutive
 securities:
 Options to
  purchase common
  stock                         1,636        984      1,709        988
 Convertible
  subordinated
  notes                         5,664      5,664      5,664      3,423
                             --------   --------   --------   --------
Weighted average
 common shares
 outstanding -
 diluted                      111,704     59,349    111,443     56,939
                             ========   ========   ========   ========
Earnings per
 share:
 Basic                       $   0.88   $   0.60   $   1.54   $   1.10
 Diluted                     $   0.84   $   0.57   $   1.48   $   1.07
Appendix - A(1)
Pro Forma Information
	   The historical consolidated financial summary and summary segment
information for the three-months and six-months ended March 31, 2001,
included in this press release, reflect only the results of
AmeriSource Health Corporation, as predecessor to the Company. In
order to enhance comparability, the following schedules as well as the
summary segment information include fiscal 2001 financial data on a
pro forma basis. Within these schedules, pro forma refers to the
combined results of AmeriSource Health Corporation and Bergen Brunswig
Corporation and are not intended to be consolidated financial
statements of AmerisourceBergen prepared in accordance with generally
accepted accounting principles and do not represent consolidated
results as if the merger had occurred at the beginning of the periods
presented. In addition, they are not necessarily indicative of the
actual results which might have occurred had the operations and
management of AmeriSource Health Corporation and Bergen Brunswig
Corporation been combined at the beginning of fiscal 2001.
	   In addition, to enhance comparability of financial information
between fiscal years, the pro forma information for fiscal 2001
excludes the amortization of goodwill and special items related to the
merger and environmental remediation and reflects the full allocation
of Bergen Brunswig Corporation's former Corporate segment to the
Pharmaceutical Distribution and PharMerica segments.
Appendix - A(2)
AmerisourceBergen
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                          Fiscal Year Ended September 30, 2001
               -------------------------------------------------------
                  First     Second      Third     Fourth
                 Quarter    Quarter    Quarter    Quarter  Fiscal Year
               -------------------------------------------------------
Operating
 revenue       $8,083,535 $8,467,976 $8,995,115 $9,052,684 $34,599,310
               =======================================================
Gross profit     $442,249   $480,035   $475,810   $482,647  $1,880,741
Distribution,
 selling and
 administrative
  (2)             293,608    303,730    295,462    304,703   1,197,503
Depreciation       13,891     14,337     14,296     14,641      57,165
Amortization (3)    1,553      1,140      1,270      1,427       5,390
               -------------------------------------------------------
Operating
 income          $133,197   $160,828   $164,782   $161,876    $620,683
               =======================================================
Gross profit to
 operating
 revenue            5.47%      5.67%      5.29%      5.33%       5.44%
Operating
 expenses to
 operating
 revenue            3.82%      3.77%      3.46%      3.54%       3.64%
Operating
 income to
 operating
 revenue            1.65%      1.90%      1.83%      1.79%       1.79%
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
(2) Excludes special items in the third and fourth quarters related to
    the merger and enviromental remediation.
(3) Excludes amortization of goodwill.
Appendix - A(3)
AmerisourceBergen - Pharmaceutical Distribution
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                      Fiscal Year Ended September 30, 2001
           -----------------------------------------------------------
              First      Second       Third      Fourth       Fiscal
             Quarter     Quarter     Quarter     Quarter       Year
----------------------------------------------------------------------
Operating
 revenue   $7,929,966  $8,335,337  $8,835,163  $8,885,145  $33,985,611
           ===========================================================
Gross
 profit      $322,096    $358,294    $358,619    $365,948   $1,404,957
Distri-
 bution,
 selling
 and
 adminis-
 trative
 (2), (3)     195,464     202,915     200,042     211,501      809,922
Depreci-
 ation          9,426       9,962       9,916      10,278       39,582
Amorti-
 zation
 (4)            1,116         703         835         972        3,626
           -----------------------------------------------------------
Operating
 income      $116,090    $144,714    $147,826    $143,197     $551,827
           ===========================================================
Gross
 profit to
 operating
 revenue        4.06%       4.30%       4.06%       4.12%        4.13%
Operating
 expenses
 to
 operating
 revenue        2.60%       2.56%       2.39%       2.51%        2.51%
Operating
 income to
 operating
 revenue        1.46%       1.74%       1.67%       1.61%        1.62%
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
(2) Excludes special items in the fourth quarter related to the merger
    and enviromental remediation.
(3) Expenses previously reported in the Corporate segment for Bergen
    Brunswig Corporation have been fully allocated to the
    Pharmaceutical Distribution and PharMerica segments for
    comparative purposes within this schedule.
(4) Excludes amortization of goodwill.
Appendix - A(4)
AmerisourceBergen - PharMerica
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                          Fiscal Year Ended September 30, 2001
                   ---------------------------------------------------
                    First     Second    Third     Fourth   Fiscal Year
                   Quarter    Quarter  Quarter   Quarter
----------------------------------------------------------------------
Operating revenue  $335,166  $339,924  $336,783  $338,135  $1,350,008
                   ===================================================
Gross profit       $120,153  $121,741  $117,191  $116,699  $  475,784
Distribution,
 selling and
 administrative
 (2), (3)            98,144   100,815    95,420    93,202     387,581
Depreciation          4,465     4,375     4,380     4,363      17,583
Amortization (4)        437       437       435       455       1,764
                   ---------------------------------------------------
Operating income   $ 17,107  $ 16,114  $ 16,956  $ 18,679  $   68,856
                   ===================================================
Gross profit to
 operating
 revenue              35.85%    35.81%    34.80%    34.51%      35.24%
Operating
 expenses to
 operating
 revenue              30.74%    31.07%    29.76%    28.99%      30.14%
Operating income
 to operating
 revenue               5.10%     4.74%     5.03%     5.52%       5.10%
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
(2) Excludes special items in the fourth quarter related to the merger
    and enviromental remediation.
(3) Expenses previously reported in the Corporate segment for Bergen
    Brunswig Corporation have been fully allocated to the
    Pharmaceutical Distribution and PharMerica segments for
    comparative purposes within this schedule.
(4) Excludes amortization of goodwill.
Appendix - A(5)
AmerisourceBergen - Intersegment Eliminations
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                           Fiscal Year Ended September 30, 2001
----------------------------------------------------------------------
                  First     Second      Third     Fourth     Fiscal
                 Quarter    Quarter    Quarter    Quarter     Year
                ------------------------------------------------------
Operating
 revenue        ($181,597) ($207,285) ($176,831) ($170,596) ($736,309)
                ======================================================
Gross profit           $0         $0         $0         $0         $0
Distribution,
 selling and
 administrative         -          -          -          -          -
Depreciation            -          -          -          -          -
Amortization            -          -          -          -          -
                ------------------------------------------------------
Operating
 income                $0         $0         $0         $0         $0
                ======================================================
(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).
CONTACT:          AmerisourceBergen, Valley Forge
                  Michael N. Kilpatric, 610/727-7118
                  mkilpatric@amerisource.com


Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..

Learn More